Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

The UBS CIO Americas wealth management equity sector strategy team came out and spotlighted its 30 most preferred stocks ...

Discussions at the Advanced Technologies & Treatments for Diabetes meeting covered CGM use in non–insulin-treated people with ...

Insulet Corporation (NASDAQ:PODD) showcases a high Return on Invested Capital (ROIC) of 16.28% and a Weighted Average Cost of ...

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

SAN DIEGO – DexCom has named Jon Coleman as chief commercial officer to oversee the company’s global commercial organization, including sales, marketing and customer experience.

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...

Dexcom (Nasdaq:DXCM) has a new chief commercial officer with significant experience at another major medtech company.